Uniphar’s (UPR) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reissued their buy rating on shares of Uniphar (LON:UPR) in a research note issued to investors on Tuesday, MarketBeat.com reports.

Uniphar Stock Up 9.6 %

UPR stock opened at GBX 195 ($2.43) on Tuesday. Uniphar has a fifty-two week low of GBX 163 ($2.03) and a fifty-two week high of GBX 256 ($3.19). The business’s 50-day moving average is GBX 174.62 and its two-hundred day moving average is GBX 198.80. The company has a debt-to-equity ratio of 119.43, a quick ratio of 0.60 and a current ratio of 0.90. The company has a market cap of £532.39 million, a price-to-earnings ratio of 1,392.86 and a beta of 0.75.

About Uniphar

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.